Fexofenadine in pediatrics: oral tablet and suspension formulations

Bibliography

• Wright AL, Holberg CJ, Martinez FD, et al. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994;94:895-901
   PubMed Web of Science ®Google Scholar
• Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 1998;81:463-8
   PubMed Web of Science ®Google Scholar
• Berger WE. Allergic rhinitis in children: diagnosis and management strategies. Paediatr Drugs 2004;6:233-50
   PubMedGoogle Scholar
• Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108:S45-53
   PubMed Web of Science ®Google Scholar
• Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000;105:S622-7
   PubMed Web of Science ®Google Scholar
• Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999;20:209-13
   PubMed Web of Science ®Google Scholar
• Skoner DP. Complications of allergic rhinitis. J Allergy Clin Immunol 2000;105:S605-9
   PubMed Web of Science ®Google Scholar
• Slavin RG. Complications of allergic rhinitis: implications for sinusitis and asthma. J Allergy Clin Immunol 1998;101:S357-60
   Google Scholar
• Polosa R, Al-Delaimy WK, Russo C, et al. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res 2005;6:153
   PubMed Web of Science ®Google Scholar
• Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005;59:674-6
   PubMed Web of Science ®Google Scholar
• Milgrom H, Bender B. Adverse effects of medications for rhinitis. Ann Allergy Asthma Immunol 1997;78:439-44; quiz 445-6
   PubMed Web of Science ®Google Scholar
• Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003;111:S835-42
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Pediatric allergic rhinitis: factors affecting treatment choice. Ear Nose Throat J 2005;84:163-8
   PubMedGoogle Scholar
• Howarth P. The choice of an H1-antihistamine for the 21st century. Clin Exp All Rev 2002;2:1-8
   Google Scholar
• Stokes J, Fenstad E, Casale TB. Managing impairment in patients with allergic rhinitis. Allergy Asthma Proc 2006;27:12-6
   PubMedGoogle Scholar
• Sanofi-Aventis. Allergra Prescribing Information. http://products.sanofi-aventis.us/allegra/allegra.html; 2007
   Google Scholar
• Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-8
   PubMed Web of Science ®Google Scholar
• Bronsky EA, Falliers CJ, Kaiser HB, et al. Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc 1998;19:135-41
   PubMed Web of Science ®Google Scholar
• Finn AF Jr, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999;104:1071-8
   PubMed Web of Science ®Google Scholar
• Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000;84:517-22
   PubMed Web of Science ®Google Scholar
• Graft DF, Bernstein DI, Goldsobel A, et al. Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:22-6
   PubMed Web of Science ®Google Scholar
• Wahn U, Meltzer EO, Finn AF Jr, et al. Fexofenadine is efficacious and safe in children (aged 6 – 11 years) with seasonal allergic rhinitis. J Allergy Clin Immunol 2003;111:763-9
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis – a pooled analysis of three studies. Pediatr Allergy Immunol 2004;15:253-60
   PubMed Web of Science ®Google Scholar
• Krishna R, Krishnaswami S, Kittner B, et al. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos 2004;25:373-87
   PubMedGoogle Scholar
• Simons FE, Bergman JN, Watson WT, Simons KJ. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 1996;98:1062-4
   PubMed Web of Science ®Google Scholar
• Milgrom H, Kittner B, Lanier R, Hampel FC. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Ann Allergy Asthma Immunol 2007;99:358-63
   PubMed Web of Science ®Google Scholar
• Hampel FC, Kittner B, Van Bavel J. Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis. Ann Allergy Asthma Immunol (In Press)
   Google Scholar
• Morrison D, Sahasranaman S. The 30 mg dose of fexofenadine HCl 6 mg/ml suspension is bioequivalent to the marketed 30 mg tablet in healthy adult subjects under fasted conditions: a randomized, crossover, open-label study. Presented at AAAAI. 2007 (Abstract 564)
   Google Scholar
• Grubbe R, Nayak A, Kittner B, Segal N. The pharmacokinetics, safety and tolerability of fexofenadine HCl 6 mg/ml suspension in children with allergic rhinitis: a multicenter, open-label, single-dose study. Presented at AAAAI. 2007 (Abstract 563).
   Google Scholar
• Triggiani M, Gentile M, Secondo A, et al. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol 2001;166:4083-91
   PubMed Web of Science ®Google Scholar
• Paolieri F, Battifora M, Riccio AM, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998;81:601-7
   PubMed Web of Science ®Google Scholar
• Abdelaziz MM, Devalia JL, Khair OA, et al. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998;101:410-20
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999;36:329-52
   PubMed Web of Science ®Google Scholar
• Kaliner MA, White MV, Economides A, et al. Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Ann Allergy Asthma Immunol 2003;90:629-34
   PubMed Web of Science ®Google Scholar
• Purohit A, N'gom AS, Deslandes B, et al. Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction. Ann Allergy Asthma Immunol 2004;93:562-7
   PubMedGoogle Scholar
• Grant JA, Riethuisen JM, Moulaert B, Devos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 h in healthy male subjects. Ann Allergy Asthma Immunol 2002;88:190-7
   PubMed Web of Science ®Google Scholar
• White M, Rothrock S, Meeves S, et al. Comparative effects of fexofenadine and montelukast on allergen-induced wheal and flare. Allergy Asthma Proc 2005;26:221-8
   PubMedGoogle Scholar
• Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy 1999;29(Suppl 3):163-70; discussion 171-3
   PubMedGoogle Scholar
• Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002;72:409-14
   PubMed Web of Science ®Google Scholar
• Robbins DK, Castles MA, Pack DJ, et al. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998;19:455-63
   PubMed Web of Science ®Google Scholar
• Lippert C, Ling J, Brown P. Mass balance and pharmacokinetics of fexofenadine HCl in healthy male volunteers. Pharm Res 1995;12:390
   Google Scholar
• Ngamphaiboon J, Direkwattanachai C, Visitsunthorn N, et al. The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis. Asian Pac J Allergy Immunol 2005;23:169-74
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002;32:133-9
   PubMed Web of Science ®Google Scholar
• Ridout F, Hindmarch I. The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. Ann Allergy Asthma Immunol 2003;90:404-10
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999;29(Suppl 3):133-42
   PubMed Web of Science ®Google Scholar
• Morgan MM, Khan DA, Nathan RA. Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines. Ann Pharmacother 2005;39:2056-64
   PubMed Web of Science ®Google Scholar
• Lehman JM, Blaiss MS. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs 2006;66:2309-19
   PubMed Web of Science ®Google Scholar